That warning is not something to ignore, but the headline is too vague. Some medications really do carry warnings about blood clots and serious cardiovascular events, while many others do not.
One important example is the JAK-inhibitor group. The FDA requires boxed warnings for tofacitinib (Xeljanz), baricitinib (Olumiant), and upadacitinib (Rinvoq) concerning increased risks of serious heart-related events such as heart attack or stroke, blood clots, cancer, and death.
U
U.S. Food and Drug Administration
+1
The risk can be particularly important in people who currently or previously smoked or who have had a heart attack, stroke, other cardiovascular disease, or previous blood clots.
U
U.S. Food and Drug Administration
🚨 Symptoms requiring emergency attention
If someone taking a medication with a clotting warning develops chest pressure or pain, sudden shortness of breath, one-sided weakness, difficulty speaking, or a suddenly swollen/painful arm or leg, emergency medical attention is warranted.
U
U.S. Food and Drug Administration
Don’t stop a prescribed medication simply because you saw this headline. The benefits may outweigh the risks, and stopping some medicines abruptly can itself be dangerous.
If you tell me the name of the tablets mentioned in the post—or send a photo of the package—I can check the specific medication and explain its actual risk.
U
Sources
